BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Shuai Ma, Zhenren Liu, Jing Pan, Shunli Zhang, Weicheng Zhou. A concise and practical stereoselective synthesis of ipragliflozin L-prolineBeilstein Journal of Organic Chemistry 2017; 13: 1064 doi: 10.3762/bjoc.13.105
2
Yoshio Nagai, Akio Ohta, Yukiyoshi Sada, Hiroyuki Kato, Yasushi Tanaka. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetesExpert Opinion on Pharmacotherapy 2017; 18(1): 13 doi: 10.1080/14656566.2016.1261110
3
Atsushi Tanaka, Toyoaki Murohara, Isao Taguchi, Kazuo Eguchi, Makoto Suzuki, Masafumi Kitakaze, Yasunori Sato, Tomoko Ishizu, Yukihito Higashi, Hirotsugu Yamada, Mamoru Nanasato, Michio Shimabukuro, Hiroki Teragawa, Shinichiro Ueda, Satoshi Kodera, Munehide Matsuhisa, Toshiaki Kadokami, Kazuomi Kario, Yoshihiko Nishio, Teruo Inoue, Koji Maemura, Jun-ichi Oyama, Mitsuru Ohishi, Masataka Sata, Hirofumi Tomiyama, Koichi Node. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT studyCardiovascular Diabetology 2016; 15(1) doi: 10.1186/s12933-016-0449-7
4
Sanjay Kalra, Kimi K. Shetty, Vertivel B. Nagarajan, Jignesh K. Ved. Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary UpdateDiabetes Therapy 2020; 11(4): 813 doi: 10.1007/s13300-020-00789-y
5
Hotimah Masdan Salim, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro, Masataka Sata. Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic MouseFrontiers in Cardiovascular Medicine 2016; 3 doi: 10.3389/fcvm.2016.00043
6
Yuka Ito, Kaori Ambe, Toshiki Hayase, Mayu Kobayashi, Masahiro Tohkin. Comparison of Efficacy of Dipeptidyl Peptidase‐4 Inhibitors and Sodium‐Glucose Co‐Transporter 2 Inhibitors Between Japanese and Non‐Japanese Patients: A Meta‐AnalysisClinical and Translational Science 2020; 13(3): 498 doi: 10.1111/cts.12732
7
Atsuo Tahara, Toshiyuki Takasu. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic miceNaunyn-Schmiedeberg's Archives of Pharmacology 2018; 391(4): 395 doi: 10.1007/s00210-018-1469-5
8
Mitsutoshi Kato, Kumiko Sakai, Kyoko Saito, Kensuke Tsutsui, Shigeo Yamashita, Noriko Kato. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozinDiabetology International 2017; 8(3): 275 doi: 10.1007/s13340-017-0307-1
9
K. Pafili, E. Maltezos, N. Papanas. The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetesExpert Opinion on Investigational Drugs 2016; 25(10): 1133 doi: 10.1080/13543784.2016.1216970
10
Adel Galal El-Shemi, Osama Adnan Kensara, Aiman Alsaegh, Mohammed Hasan Mukhtar. Pharmacotherapy with Thymoquinone Improved Pancreatic β-Cell Integrity and Functional Activity, Enhanced Islets Revascularization, and Alleviated Metabolic and Hepato-Renal Disturbances in Streptozotocin-Induced Diabetes in RatsPharmacology 2018; 101(1-2): 9 doi: 10.1159/000480018
11
Min-Koo Choi, So Jeong Nam, Hye-Young Ji, Mi Jie Park, Ji-Soo Choi, Im-Sook Song. Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and IpragliflozinPharmaceutics 2020; 12(3): 268 doi: 10.3390/pharmaceutics12030268
12
Weiping Chen, Pengyun Li, Guoqi Wang, Yang Chen, Bin Wang, Mulan Chen. Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trialsPostgraduate Medicine 2019; 131(8): 578 doi: 10.1080/00325481.2019.1655381
13
Ernest Adeghate, Sahar Mohsin, Faisal Adi, Fares Ahmed, Ali Yahya, Huba Kalász, Kornelia Tekes, Ernest A. Adeghate. An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trialsExpert Opinion on Investigational Drugs 2019; 28(9): 811 doi: 10.1080/13543784.2019.1655539
14
Eva Y Wong. A Review of Sodium Glucose Co transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes MellitusPharmacy & Pharmacology International Journal 2016; 4(2) doi: 10.15406/ppij.2016.04.00070